U.S. Attruby net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers - Observational run-in study for ...

This article is authored by Aditya Sharma, head, Process Solutions, India Region, Merck Life Science, New Delhi.

Companies are developing myostatin inhibitors for GLP-1RA-related muscle loss, but some experts question their necessity.

At its April 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) gave ...

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo's ...

HonorHealth Research Institute recently treated the first patient in a 50-site international clinical trial that will test a ...

The American Association for Cancer Research’s annual conference continued Monday with Roche offering a postmortem for its ...

The answer to this inquiry is “yes” — but maybe “no.” Will confidentiality agreements shield any prior art concerns? Once ...

Prilenia CEO Dr. Hayden purchased the development rights in exchange for limited future royalties and founded Prilenia ...

INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian ...

Explore the evolving landscape of clinical trials in drug discovery and learn about recent breakthroughs transforming the ...

Researchers from the University of Adelaide have developed a new technology for drug and functional genomics screenings, ...